Here, we demonstrate decreased survival associated with high levels of GAS6 expression in GBM, highlighting the importance of TAM kinase signaling in GBM tumorigenesis and/or therapy resistance and providing strong rationale for targeting these pathways in the clinic. This evidence concerns the gene GAS6 and glioblastoma.